{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:02:45Z","timestamp":1790402565917,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Tongxinluo capsule (TXLC) is a common drug for treating angina pectoris of coronary heart disease (CHD). In recent years, many systematic reviews (SRs) and meta-analyses (MAs) have reported the efficacy and safety of TXLC for improving angina symptoms in patients with CHD. We aimed to comprehensively evaluate the existing SRs and MAs of TXLC in treating angina pectoris of CHD, summarize the evidence quality, and provide scientific evidence and recommendations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched seven databases for relevant SRs\/MAs published up to 1 June 2023. Two reviewers independently completed the literature retrieval, screening, and data extraction. We used A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2) to evaluate the methodological quality, the Risk of Bias in Systematic Reviews (ROBIS) to assess the risk of bias, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) to determine the strength of the evidence. RevMan 5.3 was used to synthesize data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 15 SRs\/MAs, including 329 RCTs and 33,417 patients. According to the evaluation results of AMSTAR-2, only one SR was of high methodological quality, the others were very low. ROBIS assessment showed that one SR (6.67%) had a low risk, 3 SRs (20%) had an unclear risk, and 11 SRs (73.33%) had a high risk. We assessed 42 outcomes by the GRADE, 10 (23.81%) for moderate-quality evidence, 17 (40.48%) for low-quality evidence, and 15 (35.71%) for very-low-quality evidence. Mate-analysis showed that TXLC combined with conventional western medications improved electrocardiogram efficacy (RR\u2009=\u20091.38, 95% CI: 1.23\u20131.43, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.001) and angina efficacy (OR\u2009=\u20093.58, 95% CI: 3.02\u20134.24, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.001), reduced angina attack frequency (SMD\u2009=\u2009\u22120.54, 95% CI: \u22120.64 to \u22120.44, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.001) and angina duration (SMD\u2009=\u2009\u22120.42, 95% CI: \u22120.57 to \u22120.28, <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.001), with general heterogeneity. The pooled results showed that TXLC appears to have some efficacy in improving cardiac function and relieving angina symptoms, but there is limited evidence that it improves cardiovascular event rates, hemorheology, lipids, or hs-CRP. In the assessment of drug safety, TXLC was associated with different degrees of adverse drug reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on the evidence, TXLC may be effective as an adjuvant treatment for angina pectoris of CHD. However, the quality of the evidence is low, and the drug's safety must be carefully interpreted. In future studies, high-quality randomized controlled trials are needed to confirm the effectiveness and safety of TXLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>http:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>, identifier (CRD42022365372).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1229299","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T04:37:29Z","timestamp":1707799049000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of tongxinluo capsule for angina pectoris of coronary heart disease: an overview of systematic reviews and meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Liuying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peimin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lvyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daohui","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengya","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3969\/j.issn.1000-3614.2022.06.001","article-title":"Summary of the China cardiovascular health and disease report 2021","volume":"37","year":"2022","journal-title":"Chin J Circ."},{"key":"B2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1161\/01.str.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1161\/CIRCULATIONAHA.110.981407","article-title":"Nitrate therapy: new aspects concerning molecular action and tolerance","volume":"123","author":"M\u00fcnzel","year":"2011","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3969\/j.issn.1671-6450.2007.05.004","article-title":"Clinical study on the effect of tongxinluo capsule on unstable plaque of carotid atherosclerosis","volume":"5","author":"Huang","year":"2007","journal-title":"J Diff Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.7661\/CJIM.2016.04.0415","article-title":"Effects of tongxinluo capsule on platelet activating factor, vascular endothelial function, blood flow of thrombolysis in myocardial infarction in acute myocardial infarction patients after delayed percutaneous coronary intervention","volume":"36","author":"Chen","year":"2016","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"B8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3969\/j.issn.1007-614x.2019.11.057","article-title":"Study on the effect of tongxinluo capsule combined with western medicine treatment in secondary prevention of angina pectoris in coronary heart disease in the community","volume":"35","author":"Chen","year":"2019","journal-title":"Chin Community Phys"},{"key":"B9","doi-asserted-by":"publisher","first-page":"115033","DOI":"10.1016\/j.jep.2022.115033","article-title":"Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"289","author":"Lv","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15887\/j.cnki.13-1389\/r.2022.19.001","article-title":"Effect of tongxinluo capsule in the treatment of angina pectoris in coronary heart disease and its effect on patients\u2019 cardiac function","volume":"15","author":"Hu","year":"2022","journal-title":"J Clin Ration Drug Use"},{"key":"B11","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"Br Med J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: a new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"Br Med J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3969\/j.issn.1671-6450.2012.01.002","article-title":"Systematic evaluation comparing the efficacy and safety of tongxinluo capsule and fuxing danshin tablet in the treatment of angina pectoris in coronary heart disease","volume":"11","author":"Xu","year":"2012","journal-title":"J Diff Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.7501\/j.issn.1674-6376.2021.04.026","article-title":"Meta-analysis of the efficacy and safety of tongxinluo capsule in combination with conventional western medicine in the treatment of unstable angina","volume":"44","author":"Yang","year":"2021","journal-title":"Drug Eval Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.16808\/j.cnki.issn1003-7705.2018.07.071","article-title":"Meta-analysis of the efficacy of tongxinluo capsule in the treatment of unstable angina pectoris","volume":"34","author":"Wu","year":"2018","journal-title":"J Tradit Chin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3969\/j.issn.1672-2531.2011.09.016","article-title":"Systematic evaluation of the efficacy and safety of tongxinluo capsule in the treatment of coronary heart disease","volume":"11","author":"Zhou","year":"2011","journal-title":"Chin J Evid-Based Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3321\/j.issn:1672-3554.2007.05.022","article-title":"Systematic evaluation of randomized controlled trial of tongxin-luo capsule in the treatment of coronary heart disease","volume":"127","author":"He","year":"2007","journal-title":"J Zhongshan Univ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3969\/j.issn.1673-9701.2010.14.003","article-title":"Meta-analysis of the efficacy of tongxinluo capsule in the treatment of angina pectoris in coronary heart disease","volume":"48","author":"Hao","year":"2010","journal-title":"Chin Modern Doctor"},{"key":"B20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3969\/j.issn.1008-8849.2012.08.002","article-title":"Meta-analysis of the efficacy of tongxinluo capsule in the treatment of angina pectoris in coronary heart disease","volume":"21","author":"Wang","year":"2012","journal-title":"J Modern Tradit Chin Western Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3969\/j.issn.1004-745X.2012.03.037","article-title":"Systematic evaluation of the effectiveness and safety of tongxinluo capsule in the treatment of unstable angina pectoris in the elderly","volume":"21","author":"Xu","year":"2012","journal-title":"Chin Tradit Chin Med Emerg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.13422\/j.cnki.syfjx.2016090208","article-title":"Meta-analysis of the efficacy and safety of tongxinluo combined with clopidogrel in the treatment of angina pectoris in coronary heart disease","volume":"22","author":"Peng","year":"2016","journal-title":"Chin J Experiment Formulary"},{"key":"B23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3969\/J.issn.1672-6790.2015.01.022","article-title":"Meta-analysis of the effects of tongxinluo and isosorbide nitrate in the treatment of angina pectoris in coronary heart disease","volume":"18","author":"Chen","year":"2015","journal-title":"Chin J Clinical Health Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3969\/j.issn.1006-0111.2015.01.024","article-title":"A meta-analysis of the efficacy of conventional western medicine treatment combined with tongxinluo capsule in the treatment ofangina pectoris in coronary heart disease","volume":"33","author":"Fan","year":"2015","journal-title":"J Pharm Pract"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1089\/acm.2010.0788","article-title":"Is tongxinluo more effective than isosorbide dinitrate in treating angina pectoris? A systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Jia","year":"2011","journal-title":"J Altern Complement Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1089\/acm.2014.0290","article-title":"Comparative efficacy of tongxinluo capsule and beta-blockers in treating angina pectoris: meta-analysis of randomized controlled trials","volume":"21","author":"Jia","year":"2015","journal-title":"J Altern Complement Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9413704","DOI":"10.1155\/2021\/9413704","article-title":"Tongxinluo capsule combined with atorvastatin for coronary heart disease: a systematic review and meta-analysis","volume":"2021","author":"Liu","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"742978","DOI":"10.3389\/fphar.2021.742978","article-title":"Efficacy and safety of tongxinluo capsule as adjunctive treatment for unstable angina pectoris: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"805266","DOI":"10.3389\/fphar.2022.805266","article-title":"Tongxinluo may alleviate inflammation and improve the stability of atherosclerotic plaques by changing the intestinal Flora","volume":"13","author":"Qi","year":"2022","journal-title":"Front Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"116011","DOI":"10.1016\/j.jep.2022.116011","article-title":"Tongxinluo attenuates atherosclerosis by inhibiting ROS\/NLRP3\/caspase-1-mediated endothelial cell pyroptosis","volume":"304","author":"Jiang","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.12102\/j.issn.1672-1349.2021.23.008","article-title":"Effect and mechanism of ginsenoside Rg1 on cardiomyocyte apoptosis in rats with coronary heart disease","volume":"19","author":"Guo","year":"2021","journal-title":"J Cardio-Cerebrovasc Dis Integr Chin Western Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.13982\/j.mfst.1673-9078.2020.11.0510","article-title":"Protective effect of ginseng polysaccharide on myocardial mitochondria in rats with coronary heart disease","volume":"36","author":"Wan","year":"2020","journal-title":"Mod Food Sci Technol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.dcmed.2021.09.005","article-title":"Study on the mechanism of action of \u201cchuanxiong\u2014suhexiang\u2014borneol\u201d formula volatile oil in the treatment of angina pectoris and its protective effect on myocardial damage in rats based on network pharmacology","volume":"4","author":"Lei","year":"2021","journal-title":"Digit Chin Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yjmcc.2019.09.001","article-title":"Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease","volume":"136","author":"Dong","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"BSR20201349","DOI":"10.1042\/BSR20201349","article-title":"Experimental evidence and network pharmacology-based analysis reveal the molecular mechanism of tongxinluo capsule administered in coronary heart diseases","volume":"40","author":"Li","year":"2020","journal-title":"Biosci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13287-022-02969-y","article-title":"Tongxinluo-pretreated mesenchymal stem cells facilitate cardiac repair via exosomal transfer of miR-146a-5p targeting IRAK1\/NF-\u03baB p65 pathway","volume":"13","author":"Xiong","year":"2022","journal-title":"Stem Cell Res Ther"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1229299\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T04:37:58Z","timestamp":1707799078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1229299\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2024.1229299"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1229299","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"article-number":"1229299"}}